Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.46 |
| ▸ | SCN1A | P35498 | 2/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492415 | 0.85 | ALDH1A1 (0.55) | CA2HCRTR1CDK2NSD2KDM4E | |
| SCHEMBL4449107 | 0.83 | NSD2 (0.68) | CA2NPY5RNSD2KDM4ESCN1A | |
| Hydrochloric Acid SCHEMBL4449077 | 0.82 | NSD2 (0.69) | CA2NSD2KDM4ESCN1ASCN2A | |
| SCHEMBL4483058 | 0.82 | NPY1R (0.49) | CA2CDK2NPY1RNPY5RNSD2 | |
| SCHEMBL4480649 | 0.82 | MEN1 (0.53) | NSD2KDM4EALDH1A1HTT | |
| SCHEMBL4483905 | 0.81 | NSD2 (0.69) | CDK2NSD2KDM4EALDH1A1MCL1 | |
| SCHEMBL4478162 | 0.80 | CA2 (0.56) | CA2ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4448161 | 0.80 | NPY5R (0.50) | CA2NPY5RNSD2KCNA5 | |
| SCHEMBL4489171 | 0.77 | LMNA (0.51) | CA2NSD2ALDH1A1CA12 | |
| SCHEMBL4488539 | 0.76 | MCL1 (0.49) | CDK2KDM4EALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | claimed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | claimed |
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215645-A1 | Amide derivatives | OGG1, HDAC1, BCL2A1 | CA2 926/4885HCRTR1 1310/4885CDK2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.